Delivery of siRNA, miRNA, shRNA and Plasmids Guaranteed

Potent and Frequently Published Transfection Solutions


We have proven and frequently published transfection solutions. 
Powerful punch and versatility are now needed more than ever with the 
hyper growth in gene manipulation technologies like Sleeping Beauty^TM
and CRISPR-Cas9.

We have published examples of the use of our solutions for delivering siRNA, miRNA, 
shRNA and plasmids both in vitro and in vivo. here are some of your options.
i-Fect ™ -A novel cationic lipid formulation specifically 
designed for efficient delivery of 27mer DsiRNAs(dicer 
substrate small Interfering RNAs)& 21mer siRNAs (small interfering RNAs) in vitro and in vivo.
p-Fect™ -Designed to delivery plasmids, DNA or 
RNA to hard to transfect Cell Lines.

pn-Fect™ -The latest advance in transfection 
for primary neuronal cells. 
This unique reagent provides ultra-high plasmid DNA delivery 
efficiencies and low cytotoxicity compared to competitive reagents.
Here's a recent i-Fect Publication:
Liuming Jiang, Qun Wu , Tao Yang. Silencing of Id2 Alleviates 
Chronic Neuropathic Pain Following Chronic Constriction Injury.
Journal of Molecular Neuroscience\pp 1-7.First online: 15 January 2016
 

Figure: Knockdown of Id2 attenuated mechanical allodynia and thermal 

hyperalgesia in CCI rats. (a and b) PWT and PWL were measured 1 day before 

CCI and 1, 3, 7, and 14 days after intrathecal administration of shRNA-Id2.

If you are looking for transfection solutions, do not hesitate to contact me @ direct phone: 612-801-1007 or pshuster@neuromics.com. Thank you, Pete Shuster, CEO and Owner, Neuromics

Delivering TRPV1 shRNA to DRG of T8-L3 Segments of the Spinal Cord

I have reported use of our i-FectTM siRNA delivery kit for gene expression analysis studies of DOR, hTERT, The β3 subunit of the Na+,K+-ATPase, rSNSR1, NTS1. NAV1.8, Survivin, Flaviviruses and more.

This is the first publication referencing the use of i-Fect to delivery shRNA intrathecally. In this study, researchers knockdown TRPV1 Channels in DRGs to study their role in regulation of blood pressure.

Shuang-Quan Yu, Donna H. Wang. Intrathecal injection of TRPV1 shRNA leads to increases in blood pressure in rats. DOI: 10.1111/j.1748-1716.2011.02285.x. Copyright © 2011 Scandinavian Physiological Society.

Aim: The transient receptor potential vanilloid type 1 (TRPV1) channels have been implicated to play a role in blood pressure regulation. However, contribution of tissue specific TRPV1 to blood pressure regulation is largely unknown. Here we test the hypothesis that TRPV1 expressed in dorsal root ganglia (DRG) of lower thoracic and upper lumbar segments (T8-L3) of the spinal cord and their central and peripheral terminals constitutes a counter regulatory mechanism preventing the increases in blood pressure.

Methods: TRPV1 was knocked down by intrathecal injection of TRPV1 shRNA in rats. Systolic blood pressure and mean arterial pressure (MAP) were recorded. The level of TRPV1 and tyrosine hydroxylase was measured by Western blot.

Results: Intrathecal injection of TRPV1 shRNA (6 μg kg−1 per day) for 3 days increased systolic blood pressure and MAP when compared to rats that received control shRNA (control shRNA: 112±2 vs TRPV1 shRNA: 123±2 mmHg). TRPV1 expression was suppressed in T8-L3 segments of dorsal horn and DRG as well as mesenteric arteries of rats given TRPV1 shRNA. Contents of tyrosine hydroxylase, a marker of sympathetic nerves, were increased in mesenteric arteries of rats treated with TRPV1 shRNA. Pretreatment with the 1-adrenoceptor blocker, prazosin (1 mg/kg/day, p.o.), abolished the TRPV1 shRNA-induced pressor effects.

Conclusion: Our data show that selective knockdown of TRPV1 expressed in DRG of T8-L3 segments of the spinal cord and their central and peripheral terminals increases blood pressure, suggesting that neuronal TRPV1 in these segments possesses a tonic anti-hypertensive effect possibly via suppression of the sympathetic nerve activity.